The Melanoma Inhibitor of Apoptosis Protein: A Target for Spontaneous Cytotoxic T Cell Responses

Journal of Investigative Dermatology

Volumn 122, Issue 2, 2004, Pages 392-399

  Andersen, Mads Hald ^a,b   Reker, Sine ^a   Becker, Jürgen C ^a,b   Straten, Per Thor ^a  

^a DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Antigens; Cytotoxic T lymphocytes; Epitopes; Human; Peptides; Tumor immunity

Indexed keywords

ARGINYLLEUCYLALANYLSERYLPHENYLALANYLTYROSYLASPARTYLTRYPTOPHYLPROLYLLEUCI NE; ARGINYLLEUCYLGLUTAMINYLGLUTAMYLGLUTAMYLARGINYLTHREONYLCYSTEINYLLYSYLVALI NE; GLUTAMINYLLEUCYLCYSTEINYLPROLYLISOLEUCYLCYSTEINYLARGINYLALANYLPROLYLVALI NE; EPITOPE; GLUTAMINYLISOLEUCYLLEUCYLGLYCYLGLUTAMINYLLEUCYLARGINYLPROLYLLEUCINE; GLUTAMINYLLEUCYLPROLYLTHREONYLPROLYLARGINYLARGINYLGLUTAMINYLVALINE; GLYCYLMETHIONYLGLYCYLSERYLGLUTAMINYLGLUTAMINYLLEUCYLARGINYLLEUCINE; HLA A2 ANTIGEN; ISOLEUCYLLEUCYLLYSYLGLUTAMINYLPROLYLVALYLHISTIDYLGLYCINE; LEUCYLLEUCYLARGINYLSERYLLYSYLGLYCYLARGINYLASPARTYLPHENYLALANYLVALINE; LEUCYLTHREONYLALANYLGLUTAMINYLVALYLPROLYLPROLYLGLUTAMINYLLEUCINE; PEPTIDE DERIVATIVE; PROLYLLEUCYLTHREONYLALANYLGLUTAMYLVALYLPROLYLPROLYLGLUTAMYLLEUCINE; SERYLISOLEUCYLVALYLPHENYLALANYLVALYLPROLYLCYSTEINYLGLYCYLHISTIDYLLEUCINE; SERYLLEUCYLGLYCYLSERYLPROLYLVALYLLEUCYLGLYCYLLEUCINE; UNCLASSIFIED DRUG; VALYLLEUCYLGLUTAMYLPROLYLPROLYLGLYCYLALANYLARGINYLASPARTYLVALINE;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; BLOOD STAIN; CANCER INHIBITION; CELL INFILTRATION; CELL ISOLATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE LOSS; HLA TYPING; HUMAN; HUMAN CELL; MELANOMA CELL; ONCOGENE; PERIPHERAL CIRCULATION; PHENOTYPE; PRIORITY JOURNAL; TUMOR CELL;

EID: 1442323601     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.0022-202X.2004.22242.x     Document Type: Article

References (39)

1. Andersen MH, Bonfill JE, Neisig A, et al: Phosphorylated peptides can be transported by TAP molecules, presented by class I MHC molecules, and recognized by phosphopeptide-specific CTL. J Immunol 163:3812-3818, 1999a
2. Andersen MH, Sondergaard I, Zeuthen J, Elliott T, Haurum JS: An assay for peptide binding to HLA-Cw*0102. Tissue Antigens 54:185-190, 1999b
3. Andersen MH, Tan L, Sondergaard I, Zeuthen J, Elliott T Haurum JS; Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules. Tissue Antigens 55:519-531, 2000
4. Andersen MH, Pedersen LO, Becker JC, thor Straten P: Identification of a cytotoxic T lymphocyte response to the apoptose inhibitor protein survivin in cancer patients. Cancer Res 61:869-872, 2001a
5. Andersen MH, Pedersen LO, Capeller B, Brocker EB, Becker JC, thor Straten P: Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients. Cancer Res 61:5964-5968, 2001b
6. Ashhab Y, Alian A, Polliack A, Panet A, Ben Yehuda D: Two splicing variants of a new inhibitor of apoptosis gene with different biological properties and tissue distribution pattern. FEBS Lett 20: 495:56-60, 2001
7. Becker JC, Schwinn A, Dummer R, Burg G, Brocker EB: Lesion-specific activation of cloned human tumor-infiltrating lymphocytes by autologous tumor cells: Induction of proliferation and cytokine production. J Invest Dermatol 101:15-21, 1993
8. Berke Z, Andersen MH, Pedersen M, Fugger L, Zeuthen J, Haurum JS: Peptides spanning the junctional region of both the abl/bcr and the bcr/abl fusion proteins bind common HLA class I molecules. Leukemia 14:419-426, 2000
9. Chen Y, Kramer DL, Li F, Porter CW: Loss of inhibitor of apoptosis proteins as a determinant of polyamine analog-induced apoptosis in human-melanoma cells. Oncogene 22:4964-4972, 2003
10. Cormier JN, Abati A, Fetsch P, Hijazi YM, Rosenberg SA, Marincola FM, Topalian SL: Comparative analysis of the in vivo expression of tyrosinase, MART-1/ Melan-A, and gp100 in metastatic melanoma lesions: Implications for immunotherapy. J Immunother 21:27-31, 1998
11. D'Souza S, Rimoldi D, Lienard D, Lejeune F, Cerottini JC, Romero P: Circulating Melan-A/Mart-1 specific cytolytic T lymphocyte precursors in HLA-A2 -melanoma patients have a memory phenotype. Int J Cancer 78:699-706, 1998
12. Griffioen M, Borghi M, Schrier PI, Osanto S: Detection and quantification of CD8(+) T cells specific for HLA-A*0201-binding melanoma and viral peptides by the IFN-gamma-ELISPOT assay. Int J Cancer 93:549-555, 2001
13. Herr W, Ranieri E, Gambotto A, Kierstead LS, Amoscato AA, Gesualdo L, Storkus WJ: Identification of naturally processed and HLA-presented Epstein-Barr virus peptides recognized by CD4(+) or CD8(+) T lymphocytes from human blood. Proc Natl Acad Sci USA 96:12033-12038, 1999
14. Heslop HE, Rooney CM: Adoptive cellular immunotherapy for EBV lymphoproliferative disease. Immunol Rev 157:217-222, 1997
15. Jaattela M: Escaping cell death: Survival proteins in cancer. Exp Cell Res 248:30-43, 1999
16. Jäger E, Ringhoffer M, Arand M, et al: Cytolytic T cell reactivity against melanoma-associated differentiation antigens in peripheral blood of melanoma patients and healthy individuals. Melanoma Res 6:419-425, 1996
17. Jäger E, Ringhoffer M, Altmannsberger M, et al: Immunoselection in vivo: Independent loss of MHC class I and melanocyte differentiation antigen expression in metastatic melanoma. Int J Cancer 71:142-147, 1997
18. Kasof GM, Gomes BC: Livin, a novel inhibitor of apoptosis protein family member. J Biol Chem 276:3238-3246, 2001
19. Kirkin AF, Petersen TR, Olsen AC, Li L, thor Straten P, Zeuthen J: Generation of human-melanoma specific T lymphocyte clones defining novel cytolytic targets with panels of newly established melanoma cell lines. Cancer Immunol Immunother 41:71-81, 1995
20. Lee KH, Panelli MC, Kim CJ, et al: Functional dissociation between local and systemic immune response during anti-melanoma peptide vaccination. J Immunol 161:4183-4194, 1998
21. Marchand M, van Baren N, Weynants P, et al: Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer 80:219-230, 1999
22. McCutcheon M, Wehner N, Wensky A, et al: A sensitive ELISPOTassay to detect low-frequency human T lymphocytes. J Immunol Methods 210:149-166, 1997
23. Moudgil KD, Sercarz EE: Can antitumor immune responses discriminate between self and nonself? Immunol Today 15:353-355, 1994
24. Parkhurst MR, Salgaller ML, Southwood S, Robbins PF, Sette A, Rosenberg SA, Kawakami Y: Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J Immunol 157:2539-2548, 1996
25. Pass HA, Schwarz SL, Wunderlich JR, Rosenberg SA: Immunization of patients with melanoma peptide vaccines: Immunologic assessment using the ELISPOT assay [see comments]. Cancer J Sci Am 4:316-323, 1998
26. Rosenberg SA: Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst 20:1635-1644, 1996
27. Rosenberg SA, Yang JC, Schwartzentruber DJ, et al: Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 4:321-327, 1998
28. Schelbenbogen C, Sun Y, Keilholz U, et al: Identification of known and novel immunogenic T-cell epitopes from tumor antigens recognized by peripheral blood T cells from patients responding to IL-2-based treatment. Int J Cancer 20: 98:409-414, 2002
29. Schmollinger JC, Vonderheide RH, Hoar KM, et al: Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for Immune-mediated tumor destruction. Proc Natl Acad Sci USA 100:3398-3403, 2003
30. Schrama D, Andersen MH, Terheyden P, Schroder L, Pedersen LO, thor Straten P, Becker JC: Oligoclonal T-cell receptor usage of melanocyte differentiation antigen-reactive T cells in stage IV melanoma patients. Cancer Res 61:493-496, 2001
31. Schrama D, Pedersen LO, Keikavoussi P, et al: Aggregation of antigen-specific T cells at the inoculation site of mature dendritic cells. J Invest Dermatol 119:1443-1448, 2002
32. thor Straten P, Guldberg P, Grønbaak K, Zeuthen J, Becker JC: In situ T-cell responses against melanoma comprise high numbers of locally expanded T-cell clonotypes. J Immunol 163:443-447, 1999
33. Thurner B, Haendle I, Roder C, et al: Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med 190:1669-1678, 1999
34. Van den Eynde BJ, Boon T: Tumor antigens recognized by T lymphocytes. Int J Clin Lab Res 27:81-86, 1997
35. Vucic D, Stennicke HR, Pisabarro MT, Salvesen GS, Dixit VM: ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas. Curr Biol 10:1359-1366, 2000
36. Yee C, Thompson JA, Roche P, et al: Melanocyte destruction after antigen-specific immunotherapy of melanoma: Direct evidence of T cell-mediated vitiligo. J Exp Med 192:1637-1644, 2000
37. Yewdell JW, Bennink JR: Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol 17:51-88, 1999
38. Zaffaroni N, Pennati M, Colella G, et al: Expression of the anti-apoptotic gene survivin correlates with taxol resistance in human ovarian cancer. Cell Mol Life Sci 59:1406-1412, 2002
39. Zeh HJ, Perry-Lalley D, Dudley ME, Rosenberg SA, Yang JC: High avidity CTLs for two self-antigens demonstrate superior in vitro and in vivo antitumor efficacy. J Immunol 162:989-994, 1999